1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Pipeline Review, H2 2020, provides an overview of the Rabies (Infectious Disease) pipeline landscape.
Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Rabies - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 4, 5, 1, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 6 and 1 molecules, respectively.
Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Rabies - Overview
- Rabies - Therapeutics Development
- Rabies - Therapeutics Assessment
- Rabies - Companies Involved in Therapeutics Development
- Rabies - Drug Profiles
- Rabies - Dormant Projects
- Rabies - Discontinued Products
- Rabies - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Rabies, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Companies, H2 2020 (Contd..1), H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Rabies - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
- Rabies - Pipeline by Cadila Healthcare Ltd, H2 2020
- Rabies - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2020
- Rabies - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H2 2020
- Rabies - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2020
- Rabies - Pipeline by CPL Biologicals Pvt Ltd, H2 2020
- Rabies - Pipeline by Curevac AG, H2 2020
- Rabies - Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, H2 2020
- Rabies - Pipeline by GlaxoSmithKline Plc, H2 2020
- Rabies - Pipeline by Humabs BioMed SA, H2 2020
- Rabies - Pipeline by Indian Immunologicals Ltd, H2 2020
- Rabies - Pipeline by Mid-Atlantic BioTherapeutics, Inc., H2 2020
- Rabies - Pipeline by Molecular Targeting Technologies Inc, H2 2020
- Rabies - Pipeline by NanoViricides Inc, H2 2020
- Rabies - Pipeline by North China Pharmaceutical Group New Drug Research and Development Co Ltd, H2 2020
- Rabies - Pipeline by Oita University Institute of Advanced Medicine Inc, H2 2020
- Rabies - Pipeline by Sanofi, H2 2020
- Rabies - Pipeline by Shandong Yidu Biotechnology Co Ltd, H2 2020
- Rabies - Pipeline by Shanghai Qingsai Biotechnology Co Ltd, H2 2020
- Rabies - Pipeline by Synermore Biologics Co Ltd, H2 2020
- Rabies - Pipeline by Trellis Bioscience Inc, H2 2020
- Rabies - Pipeline by Univercells SA, H2 2020
- Rabies - Pipeline by Yisheng Biopharma Co Ltd, H2 2020
- Rabies - Dormant Projects, H2 2020
List of Figures
- Number of Products under Development for Rabies, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Targets, H2 2020
- Number of Products by Stage and Targets, H2 2020
- Number of Products by Mechanism of Actions, H2 2020
- Number of Products by Stage and Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Beijing Minhai Biotechnology Co Ltd
- Cadila Healthcare Ltd
- Changchun Bcht Biotechnology Co Ltd
- Chengdu Rongsheng Pharmaceutical Co Ltd
- Chongqing Zhifei Biological Products Co Ltd
- CPL Biologicals Pvt Ltd
- Curevac AG
- Genrix (Shanghai) Biopharmaceutical Co Ltd
- GlaxoSmithKline Plc
- Humabs BioMed SA
- Indian Immunologicals Ltd
- Mid-Atlantic BioTherapeutics, Inc.
- Molecular Targeting Technologies Inc
- NanoViricides Inc
- North China Pharmaceutical Group New Drug Research and Development Co Ltd
- Oita University Institute of Advanced Medicine Inc
- Sanofi
- Shandong Yidu Biotechnology Co Ltd
- Shanghai Qingsai Biotechnology Co Ltd
- Synermore Biologics Co Ltd
- Trellis Bioscience Inc
- Univercells SA
- Yisheng Biopharma Co Ltd
